Molecular Partners AG (MOLN.SW)
CHF 3.24
(2.53%)
CHF 3.24
(2.53%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 7.03 Million CHF | -96.29% |
| 2022 | 189.55 Million CHF | 1931.68% |
| 2021 | 9.33 Million CHF | -0.15% |
| 2020 | 9.34 Million CHF | -54.16% |
| 2019 | 20.38 Million CHF | 96.84% |
| 2018 | 10.35 Million CHF | -48.27% |
| 2017 | 20.01 Million CHF | -13.13% |
| 2016 | 23.04 Million CHF | -20.88% |
| 2015 | 29.11 Million CHF | 9.37% |
| 2014 | 26.62 Million CHF | -17.87% |
| 2013 | 32.41 Million CHF | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 2.73 Million CHF | 165.31% |
| 2024 Q3 | 681 Thousand CHF | -56.09% |
| 2024 Q2 | 1.55 Million CHF | -43.35% |
| 2023 Q2 | 415 Thousand CHF | -86.39% |
| 2023 Q1 | 3.05 Million CHF | 13.26% |
| 2023 Q4 | 1.03 Million CHF | -59.39% |
| 2023 Q3 | 2.54 Million CHF | 512.29% |
| 2023 FY | 7.03 Million CHF | -96.29% |
| 2022 Q3 | 2.33 Million CHF | -80.11% |
| 2022 Q1 | 172.77 Million CHF | 9633.97% |
| 2022 FY | 189.55 Million CHF | 1931.68% |
| 2022 Q4 | 2.69 Million CHF | 15.23% |
| 2022 Q2 | 11.74 Million CHF | -93.2% |
| 2021 Q1 | 815 Thousand CHF | -47.25% |
| 2021 Q2 | 3.21 Million CHF | 294.23% |
| 2021 FY | 9.33 Million CHF | -0.15% |
| 2021 Q4 | 1.77 Million CHF | -49.67% |
| 2021 Q3 | 3.52 Million CHF | 9.77% |
| 2020 Q2 | 3.71 Million CHF | -2.47% |
| 2020 Q3 | 283 Thousand CHF | -92.37% |
| 2020 FY | 9.34 Million CHF | -54.16% |
| 2020 Q1 | 3.8 Million CHF | 11.39% |
| 2020 Q4 | 1.54 Million CHF | 445.94% |
| 2019 Q2 | 6.77 Million CHF | 0.0% |
| 2019 FY | 20.38 Million CHF | 96.84% |
| 2019 Q4 | 3.41 Million CHF | 0.0% |
| 2019 Q3 | 3.41 Million CHF | -49.58% |
| 2019 Q1 | 6.77 Million CHF | 1380.98% |
| 2018 Q4 | 457.5 Thousand CHF | 0.0% |
| 2018 FY | 10.35 Million CHF | -48.27% |
| 2018 Q1 | 4.72 Million CHF | -32.59% |
| 2018 Q2 | 4.72 Million CHF | 0.0% |
| 2018 Q3 | 457.5 Thousand CHF | -90.31% |
| 2017 Q3 | 7 Million CHF | 140.45% |
| 2017 FY | 20.01 Million CHF | -13.13% |
| 2017 Q4 | 7 Million CHF | 0.0% |
| 2017 Q2 | 2.91 Million CHF | -6.06% |
| 2017 Q1 | 3.1 Million CHF | -19.27% |
| 2016 Q3 | 5.7 Million CHF | -15.46% |
| 2016 Q4 | 3.84 Million CHF | -32.63% |
| 2016 FY | 23.04 Million CHF | -20.88% |
| 2016 Q1 | 6.8 Million CHF | -15.2% |
| 2016 Q2 | 6.74 Million CHF | -0.85% |
| 2015 Q3 | 9.9 Million CHF | 81.71% |
| 2015 Q2 | 5.44 Million CHF | -6.07% |
| 2015 FY | 29.11 Million CHF | 9.37% |
| 2015 Q1 | 5.8 Million CHF | -13.76% |
| 2015 Q4 | 8.01 Million CHF | -19.0% |
| 2014 Q4 | 6.72 Million CHF | 0.37% |
| 2014 Q3 | 6.7 Million CHF | 1.23% |
| 2014 Q2 | 6.61 Million CHF | 0.0% |
| 2014 Q1 | 6.61 Million CHF | -0.56% |
| 2014 FY | 26.62 Million CHF | -17.87% |
| 2013 Q2 | 8.1 Million CHF | 0.0% |
| 2013 FY | 32.41 Million CHF | 0.0% |
| 2013 Q1 | 8.1 Million CHF | 0.0% |
| 2013 Q4 | 6.65 Million CHF | -17.87% |
| 2013 Q3 | 8.1 Million CHF | 0.0% |
| 2012 Q4 | 8.1 Million CHF | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Addex Therapeutics Ltd | 1.61 Million CHF | -335.2% |
| BB Biotech AG | -199.56 Million CHF | 103.527% |
| Basilea Pharmaceutica AG | 157.63 Million CHF | 95.535% |
| Evolva Holding SA | 9.43 Million CHF | 25.428% |
| Idorsia Ltd | 152.38 Million CHF | 95.381% |
| Kuros Biosciences AG | 33.56 Million CHF | 79.031% |
| Relief Therapeutics Holding AG | 6.03 Million CHF | -16.658% |
| Santhera Pharmaceuticals Holding AG | 103.41 Million CHF | 93.194% |